Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: Results of a randomized, open-label, three-period crossover study in healthy volunteers

Clinical Therapeutics

Volumn 26, Issue 10, 2004, Pages 1630-1636

  Cantarini, Mireille V ^a   McFarquhar, Teresa ^a   Smith, Robert P ^a   Bailey, Chris ^a   Marshall, Anna L ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

bioavailability; epidermal growth factor receptor; gefitinib; head and neck cancer; high performance liquid chromatography with tandem mass spectrometric detection; pharmacokinetics

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; GEFITINIB;

ADULT; AGE DISTRIBUTION; AREA UNDER THE CURVE; ARTICLE; BODY HEIGHT; BODY WEIGHT; CANNULA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISPERSION; DRINKING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG SAFETY; DRY SKIN; GEOMETRY; HUMAN; MALE; NASOGASTRIC TUBE; NORMAL HUMAN; NOSE FEEDING; PHASE 1 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; RHINORRHEA; SINGLE DRUG DOSE; SKIN TOXICITY; TABLET; TANDEM MASS SPECTROMETRY; TREATMENT WITHDRAWAL; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BEVERAGES; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; EPIDERMAL GROWTH FACTOR; HUMANS; INTUBATION, GASTROINTESTINAL; MALE; MIDDLE AGED; PROTEIN-TYROSINE KINASES; QUINAZOLINES; TABLETS;

EID: 10444231159     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2004.10.011     Document Type: Article

References (14)

1. Nicholson R.I., Gee J.M., and Harper M.E. EGER and cancer prognosis Eur J Cancer 37 Suppl 4 2001 S9 S15
2. Salomon D.S., Brandt R., Ciardiello F., and Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies Crit Rev Oncol Hematol 19 1995 183 232
3. Fukuoka M., Yano S., and Giaccone G. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced nonsmall-cell lung cancer J Clin Oncol 21 2003 2237 2246
4. Kris M.G., Natale R.B., and Herbst R.S. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lungcancer: A randomized trial JAMA 290 2003 2149 2158
5. Fukuoka M., Kris M., and Giaccone G. Phase II trials of gefitinib ('Iressa,' ZD1839): Rapid and durable objective responses in patients with advanced non-smallcell lung cancer (IDEAL 1 and IDEAL 2) Poster presented at: 10th World Conference on Lung Cancer Vancouver, Canada August 10-14, 2003
6. Cohen E.E., Rosen F., and Stadler W.M. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck J Clin Oncol 21 2003 1980 1987
7. Abstract 2021 Cohen E.E., Stenson K., and Gustin D.M. A Phase II study of 250-mg gefitinib (ZD 1839) monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) Proc Am Soc Clin Oncol 22 2003 502
8. Owen W. ABC of the upper gastrointestinal tract. Dysphagia BMJ 323 2001 850 853
9. Available at US Food and Drug Administration Center for Drug Evaluation and Research Accessed Guidance for Industry. Statistical Approaches to Establishing Bioeauivalence August 12, 2004
10. Available at European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products (CPMP) Accessed Note for Guidance on the Investigation of Bioavailability and Bioeauivalence August 12, 2004
11. Available at US Food and Drug Administration Center for Drug Evaluation and Research Accessed August 12, 2004 Guidance for Industry. Bioavailability and Bioeauivalence Studies for Orally Administered Drug Products--General Considerations 2002
12. Abstract OII-C-4 Bradford D.A., Mant T.G., Amin D.A., and Angell M.P. The placebo effect: Adverse events commonly seen in healthy volunteer phase I drug trials: An observation on findings, comparing active with placebo treatment Clin Pharmacol Ther 73 2003 P92
13. Rosenzweig P., Brohier S., and Zipfel A. The placebo effect in healthy volunteers: Influence of experimental conditions on the adverse events profile during Phase I studies Clin Pharmacol Ther 54 1993 578 583
14. Swaisland H., Laight A., and Stafford L. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthyvolunteers Clin Pharmacohinet 40 2001 297 306